Position in EXEL
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$900,050
+$293,843 QoQ
Shares Held
16,542
+17.0% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#348
of 751 holders
Holding Since
Mar 2022
11 quarters on record
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PARK AVENUE SECURITIES LLC holds $18,019,918 across 22 Biotechnology names. EXEL ranks #5 (5.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
10,198 | $5,065,652 | |
| 2 | RPRX |
Royalty Pharma plc
|
46,965 | $2,633,327 | |
| 3 | INSM |
INSMED Inc
|
9,927 | $1,058,416 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,563 | $974,593 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
16,542 | $900,050 | |
| 6 | ARGX |
Argenx SE
|
956 | $886,948 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
3,608 | $869,419 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
10,089 | $789,666 |
All Filings in EXEL
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $900,050 | 16,542 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $606,207 | 14,134 | Shares | Sole | 2026-04-07 | |
| 2025-12-31 | $379,392 | 8,656 | Shares | Sole | 2026-01-05 | |
| 2025-09-30 | $521,908 | 12,637 | Shares | Sole | 2025-10-23 | |
| 2025-06-30 | $388,432 | 8,812 | Shares | Sole | 2025-07-14 | |
| 2025-03-31 | $271,657 | 7,358 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $221,478 | 6,651 | Shares | Sole | 2025-01-14 | |
| 2022-12-31 | $185,582 | 11,570 | Shares | Sole | 2023-01-24 | |
| 2022-09-30 | $199,104 | 12,698 | Shares | Sole | 2022-11-01 | |
| 2022-06-30 | $326,499 | 15,682 | Shares | Sole | 2022-07-27 | |
| 2022-03-31 | $297,543 | 13,125 | Shares | Sole | 2022-04-29 | |
| No filing history on record for this holder in this stock. | ||||||